EPLERENONE

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category UNKNOWN
ATC C03DA04
UNII 6995V82D0B
EPA CompTox DTXSID2046094

Structure

InChI Key JUKPWJGBANNWMW-VWBFHTRKSA-N
Smiles COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13
InChI
InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C24H30O6
Molecular Weight 414.5
AlogP 3.12
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 1.0
Polar Surface Area 82.2
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 30.0

Bioactivity

Mechanism of Action Action Reference
Mineralocorticoid receptor antagonist ANTAGONIST DailyMed
Protein: Mineralocorticoid receptor
Description: Mineralocorticoid receptor
Organism : Homo sapiens
P08235 ENSG00000151623
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 1
- 18000 - 3162 -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 2
100 63-2600 - 126 44-111
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 3
- - - 19953 -
Assay Description Organism Bioactivity Reference
Antagonist activity at Gal4-fused mineralocorticoid receptor expressed in human HuH7 cells assessed as inhibition of aldosterone-induced receptor activation by luciferase reporter gene assay None 135.0 nM
Antagonist activity at mineralocorticoid receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay None 122.0 nM
Antagonist activity at Gal4-tagged mineralocorticoid receptor expressed in human Huh7 cells by luciferase reporter gene assay None 122.0 nM
Antagonist activity at human mineralocorticoid receptor assessed as inhibition of binding to coactivator peptide by NH Pro assay Homo sapiens 240.0 nM
Antagonist activity at mineralocorticoid receptor (unknown origin) by PathHunter assay Homo sapiens 244.0 nM
Antagonist activity at mineralocorticoid receptor (unknown origin) by Gal4-based cellular assay Homo sapiens 122.0 nM
In vivo antagonist activity at MR in rat assessed as inhibition aldosterone-induced decrease in urinary sodium/potassium ratio at 30 mg/kg, po after 8 hrs Rattus norvegicus 8.0 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 6.94 %
Modulation activity at human mineralocorticoid receptor in human EA.hy926 cells assessed as induction of nuclear translocation of mineralocorticoid receptor in absence of aldosterone by receptor translocation assay Homo sapiens 100.0 nM
Displacement of [3H]-aldosterone to human mineralocorticoid receptor LBD by radiometric binding assay Homo sapiens 125.89 nM
Antagonist activity at gal4-fused human mineralocorticoid receptor LBD expressed in UAS-MR-bla HEK293 cells by luciferase reporter gene assay Homo sapiens 794.33 nM
Antagonist activity at human gal4-fused mineralocorticoid receptor LBD expressed in UAS-MR-bla HEK293 by luciferase reporter gene assay relative to control Homo sapiens 111.0 %
Antagonist activity at full length human mineralocorticoid receptor expressed in human U2OS cells by luciferase reporter gene assay Homo sapiens 398.11 nM
Antagonist activity at full length human mineralocorticoid receptor in expressed in human U2OS cells by luciferase reporter gene assay relative to control Homo sapiens 100.0 %
Antagonist activity at gal4-fused rat mineralocorticoid receptor LBD in expressed in human U2OS cells by luciferase reporter gene assay Rattus norvegicus 39.81 nM
Antagonist activity at gal4-fused rat mineralocorticoid receptor LBD in expressed in human U2OS cells by luciferase reporter gene assay relative to control Rattus norvegicus 102.0 %
Modulation activity at human mineralocorticoid receptor in human EA.hy926 cells assessed as blocking of nuclear translocation of mineralocorticoid receptor in presence of aldosterone by receptor translocation assay Homo sapiens 63.1 nM
Modulation activity at human mineralocorticoid receptor in human EA.hy926 cells assessed as blocking of nuclear translocation of mineralocorticoid receptor in presence of aldosterone by receptor translocation assay relative to control Homo sapiens 44.0 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 7.615 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.15 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.15 %
Antagonist activity at human full-length MCR assessed as inhibition of receptor binding to co-activator peptide by PathHunter assay Homo sapiens 244.0 nM

Related Entries

Environmental Exposure

Environmental Exposure Map
Countries
Croatia

Cross References

Resources Reference
ChEBI 31547
ChEMBL CHEMBL1095097
DrugBank DB00700
DrugCentral 1032
FDA SRS 6995V82D0B
Human Metabolome Database HMDB0014838
Guide to Pharmacology 2876
KEGG C12512
PDB YNU
PubChem 443872
SureChEMBL SCHEMBL21515
ZINC ZINC000003985982
CONTENTS